2 completed. 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow SEP363856: new trials by email Literature Review of SEP363856 trials Research Report on SEP363856
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. SEP363856, quetiapine XR - Schizophrenia | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 305 | 2019-11-21 | 2025-12-31 |
| This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation. SEP363856, Placebo - Narcolepsy | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 18 | 2014-06-05 | 2024-06-26 |
Narcolepsy (1) · Schizophrenia (1)
Otsuka Pharmaceutical Development & Commercialization, Inc. (2)
United States (2) · Romania (1) · Russia (1) · Ukraine (1)
2019 (1)